

DAFTAR PUSTAKA

1. World Health Organization. Absolute Numbers, Incidence, Both Sexes, In 2022 [Internet]. 2022 [cited 2025 Feb 22]. Available from: https://gco.iarc.fr/today/en/dataviz/pie?mode=population&group_populations=0&types=0
2. Hindley R. Prostate Cancer. Bott SR, Ng KL, editors. Brisbane, Australia: Exon Publications; 2021.
3. WHO International Agency for Research on Cancer. Global Fact Sheet. Glob Cancer Obs. 2022;
4. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89.
5. WHO International Agency for Research on Cancer. Indonesia Fact Sheet. Glob Cancer Obs. 2022;
6. Louisa J, Sumadi IWJ, Saputra H, Ekawati NP. Profil Klinikopatologi Karsinoma Prostat di Rumah Sakit Umum Pusat Prof. Dr. I.G.N.G. Ngoerah Denpasar Periode Tahun 2017-2020. Intisari Sains Medis. 2023;14(1):118–23.
7. Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic Review and Meta-Analysis of the Diagnostic Accuracy of Prostate-Specific Antigen (PSA) for the Detection of Prostate Cancer in Symptomatic Patients. BMC Med. 2022;20:1–11.
8. Figueiredo A, Costa L, Mauricio MJ, Figueira L, Ramos R, Martins-da-Silva C. Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends. Clin Drug Investig. 2022;42(8):631–42.
9. Wang J, Abudurexiti M, Shao N, Wei Y, Zhu Y, Ye D wei. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. Eur Urol Focus. 2020;6:53–62.
10. McAninch JW, Lue TF. Smith & Tanagho's General Urology. 19th Ed. San Francisco, California: McGraw Hill; 2020.
11. Nuraini D. Hubungan Skor Gleason dengan Kadar Prostate Specific Antigen (PSA) pada Pasien Karsinoma Prostat di RSUP Dr. M.Djamil Padang. Universitas Andalas; 2019.
12. Tzenios N, Tzanios ME, Chahine M. The Impact of Body Mass Index on Prostate Cancer. Medicine (Baltimore). 2022;101(45):1–15.
13. Lavalette C, Cordina Duverger E, Artaud F, Rébillard X, Lamy PJ, Trétarre B, et al. Body Mass Index Trajectories and Prostate Cancer Risk: Results From the EPICAP Study. Cancer Med. 2020;9:6421–2.

14. Ross MH, Pawlina W. Histology: A Text and Atlas with Correlated Cell and Molecular Biology. 7th Ed. Human Pathology. Philadelphia: Wolters Kluwer Health; 2016. 816 p.
15. Ikbal M, Mahrani I, Lubis IA, Astria A. Profil Penderita Karsinoma Prostat di RSUD Dr. Pirngadi Medan Tahun 2018 - 2020. Ibnu Sina J Kedokt dan Kesehat - Fak Kedokt Univ Islam Sumatera Utara. 2023;22(2).
16. Pamungkas PB. Hubungan Kadar Prostate Specific Antigen (PSA) Dengan Derajat Histopatologi Kanker Prostat. J Med Utama. 2021;02(04):1122–6.
17. Belkahla S, Nahvi I, Biswas S, Nahvi I, Ben Amor N. Advances and development of prostate cancer, treatment, and strategies: A systemic review. Front Cell Dev Biol. 2022;1–11.
18. WHO International Agency for Research on Cancer. Estimated Number of New Cases From 2022 to 2045, Both Sexes, Age [0-85+] [Internet]. 2024 [cited 2025 Mar 1]. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=27&single_unit=50000
19. American Cancer Society. Prostate Cancer Risk Factors Prostate Cancer Causes, Risk Factors, and Prevention. 2023;
20. Hwang T, Oh H, Lee JA, Kim EJ. Prostate Cancer Risk Prediction Based on Clinical Factors and Prostate-Specific Antigen. BMC Urol. 2023;23:1–8.
21. Wasim S, Lee SY, Kim J. Complexities of Prostate Cancer. Int J Mol Sci. 2022;23:1–20.
22. Purnomo BB. Dasar-Dasar Urologi. 3th Ed. Jakarta: Sagung Seto; 2011.
23. Berenguer C V., Pereira F, Câmara JS, Pereira JAM. Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis. Curr Oncol. 2023;30:2300–21.
24. Oczkowski M, Dziendzikowska K, Pasternak-Winiarska A, Włodarek D, Gromadzka-Ostrowska J. Dietary Factors and Prostate Cancer Development, Progression, and Reduction Michał. Nutrients. 2021;13.
25. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018;8.
26. Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, et al. Epidemiology, Staging and Management of Prostate Cancer. Med Sci. 2020;8.
27. Olivas A, Price RS. Obesity, Inflammation, and Advanced Prostate Cancer. Nutr Cancer. 2020;
28. Sierra MS, Soerjomataram I, Forman D. Prostate Cancer Burden in Central and South America. Cancer Epidemiol. 2016;44:S131–40.
29. Bleyer A, Spreafico F, Barr R. Prostate Cancer in Young Men: An Emerging Young Adult and Older Adolescent Challenge. Cancer. 2020;

30. Harrison S, Tilling K, Turner EL, Martin RM, Lennon R, Lane JA, et al. Systematic Review and Meta-Analysis of The Associations Between Body Mass Index, Prostate Cancer, Advanced Prostate Cancer, and Prostate-Specific Antigen. *Cancer Causes Control*. 2020;31:431–49.
31. Lui DTW, Ako J, Dalal J, Fong A, Fujino M, Horton A, et al. Obesity in the Asia-Pacific Region: Current Perspectives. *J Asian Pacific Soc Cardiol*. 2024;3.
32. Van Haute M, Rondilla E, Vitug JL, Batin KD, Abrugar RE, Quitoriano F, et al. Assessment of a Proposed BMI Formula in Predicting Body Fat Percentage Among Filipino Young Adults. *Sci Rep*. 2020;10:1–14.
33. Habib A, Jaffar G, Khalid MS, Hussain Z, Zainab SW, Ashraf Z, et al. Risk Factors Associated with Prostate Cancer. *J Drug Deliv Ther*. 2021;11(2):188–93.
34. Yang X, Chen H, Zhang S, Chen X, Sheng Y, Pang J. Association of Cigarette Smoking Habits With the Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. *BMC Public Health*. 2023;23:1.
35. Ziglioli F, Patera A, Isgrò G, Campobasso D, Guarino G, Maestroni U. Impact of Modifiable Lifestyle Risk Factors for Prostate Cancer Prevention: A Review of The Literature. *Front Oncol*. 2023;
36. Kaltsas A, Chrisofos M, Symeonidis EN, Zachariou A, Stavropoulos M, Kratiras Z, et al. To Drink or Not to Drink? Investigating Alcohol's Impact on Prostate Cancer Risk. 2024;16:1–18.
37. Saranyutanon S, Deshmukh, Sachin Kumar Dasgupta S, Pai S, Singh S, Singh AP. Cancer and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research. *Cancers (Basel)*. 2020;12:1–26.
38. Panno J. *Cancer: The Role of Genes, Lifestyle, and Environment*. Revised Ed. New York: Facts on File; 2010.
39. Formaggio N, Rubin MA, Theurillat JP. Loss and Revival of Androgen Receptor Signaling in Advanced Prostate Cancer. *Oncogene*. 2021;40:1205–16.
40. Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. *Endocr Rev*. 2021;42(3):354–73.
41. Coleman WB. Molecular Pathogenesis of Prostate Cancer. In: Coleman WB, Tsongalis GJ, editors. *Essential Concepts in Molecular Pathology*. 2nd ed. Elsevier; 2020. p. 441–7.
42. Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. The Role of the Androgen Receptor in Prostate Development and Benign Prostatic Hyperplasia: A Review. *Asian J Urol*. 2020;7:191–202.
43. Phua TJ. The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective. *Medicines*. 2021;8.

44. Prakash P, Verma S, Gupta S. Risk Factors Influencing Chronic Inflammation in Neoplastic Transition to Prostate Cancer. *J Transl Genet Genomics*. 2024;8:312–27.
45. de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate Carcinogenesis: Inflammatory Storms. *Nat Rev Cancer*. 2020;
46. Bergez-Hernández F, Irigoyen-Arredondo M, Camberos AM. A Systematic Review of Mechanisms of PTEN Gene Down-Regulation Mediated by miRNA in Prostate Cancer. *Heliyon*. 2024;10:1–12.
47. Pitzen SP, Dehm SM. Basal Epithelial Cells in Prostate Development, Tumorigenesis, and Cancer Progression. *Cell Cycle*. 2023;22(11):1303–18.
48. Oseni SO, Naar C, Pavlović M, Asghar W, Hartmann JX, Fields GB, et al. The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer. *Cancers (Basel)*. 2023;15.
49. Dasgupta P, Kirby RS. *ABC of Prostate Cancer*. 1st Ed. Wiley-Blackwell. BMJ Books; 2011.
50. Archer M, Dogra N, Kyprianou N. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. *Cancers (Basel)*. 2020;12:1–24.
51. Taha SM, Weng HY, Mohammed MEI, Osman YM, N'Dri N, Mohammed SI, et al. Prostate Cancer Clinical Characteristics and Outcomes in Central Sudan. *Ecancermedicallscience*. 2020;14:1–8.
52. Oyortey MA, Adanu KK, Ali MA. The Effect of Unusual Presentation on Delayed Diagnosis of Prostate Cancer: a Case Series. *J Med Case Rep*. 2024;18:1–5.
53. Chandra Engel J, Palsdottir T, Aly M, Egevad L, Grönberg H, Eklund M, et al. Lower Urinary Tract Symptoms (LUTS) are Not Associated With an Increased Risk of Prostate Cancer in Men 50–69 Years With PSA ≥ 3 ng/ml. *Scand J Urol*. 2020;54(1):1–6.
54. Gewanter RM, Sandhu JS, Tin AL, Gross JP, Mazzarella K, Urban J, et al. Assessment of Patients With Prostate Cancer and Their Understanding of the International Prostate Symptom Score Questionnaire. *Adv Radiat Oncol*. 2023;8:2.
55. Ozah E, Imasogie DE. The Diagnostic Accuracy of Prostate-Specific Antigen and Digital Rectal Examination in the Diagnosis of Prostate Cancer at the University of Benin Teaching Hospital. *J West African Coll Surg*. 2023;13:91–5.
56. Sekhoacha M, Riet K, Motlounge P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. *Molecules*. 2022;27:1–33.

57. Udoh EA, Akaiso OE, Ukpung AE. Accuracy of Digital Rectal Examination to Diagnose Prostate Cancer Confirmed by Needle Biopsy Reports: A 3–Year Hospital-Based Study. *Ibom Med J*. 2020;13(3):156–63.
58. Chung Y, Hong SK. Evaluating Prostate Cancer Diagnostic Methods: The Role and Relevance of Digital Rectal Examination in Modern Era. *Investig Clin Urol*. 2025;1–7.
59. Zhao Y, Zhang Y, Wang X, Lin D, Chen Z. Relationship Between Body Mass Index and Concentrations of Prostate Specific Antigen: A Cross-Sectional Study. *Scand J Clin Lab Invest*. 2020;1–6.
60. Garrido MM, Bernardino RM, Marta JC, Holdenrieder S, Guimarães JT. Tumour Markers in Prostate Cancer: The Post-Prostate-Specific Antigen Era. *Ann Clin Biochem*. 2022;59(1):46–58.
61. Panzone J, Byler T, Bratslavsky G, Goldberg H. Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications. *Cancer Manag Res*. 2022;14:1209–28.
62. Daniswara CL. Pencitraan Kanker Prostat. *Cermin Dunia Kedokt*. 2020;47(2):144–8.
63. Xu G, Li JH, Xiang LH, Yang B, Chen YC, Sun YK, et al. Transrectal Ultrasound Examination of Prostate Cancer Guided by Fusion Imaging of Multiparametric MRI and TRUS: Avoiding Unnecessary mpMRI-Guided Targeted Biopsy. *Asian J Androl*. 2023;25:410–5.
64. Langley S. Urologic Cancer. Barber N, Ali A, editors. Brisbane, Australia: Exon Publications; 2022. 142 p.
65. Nath CK, Barman B, Phukan P, Sailo SL, Dey B, Nath I, et al. Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma. *J Lab Physicians*. 2020;12:44–8.
66. Chen Z, Zhang R, Lin R, Lin L, Zhu Q, Ye L, et al. Comparisons of Cancer-Specific and Overall Mortality in Patients with Biopsy- and TURP-Diagnosed Prostate Cancer: A Population-Based Propensity Score-Matching Study. *J Mens health*. 2024;20(2):72–83.
67. Yii RSL, Lim J, Sothilingam S, Yeoh WS, Fadzli AN, Ong TA, et al. Predictive Factors of Prostate Cancer Diagnosis with PSA 4.0–10.0 ng/ml in a Multi-Ethnic Asian Population, Malaysia. *Asian J Surg*. 2020;43:87–94.
68. Munjal A, Leslie SW. Gleason Score [Internet]. 2023 [cited 2025 May 2]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK553178/>
69. Prostate Cancer Early Detection, Diagnosis, and Staging [Internet]. American Cancer Society. 2025 [cited 2025 Apr 13]. Available from: <https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging.html>

70. Sun C, Yang D, Zhu J, Zhou Y, Xiang C, Wu S. Modified the 8th AJCC Staging System for Patients With Advanced Prostate Cancer: A Study Based on SEER Database. *BMC Urol.* 2022;22:1–9.
71. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. *Eur Assoc Urol.* 2025;18–57.
72. Lowenstein LM, Choi NJ, Hoffman KE, Volk RJ, Loeb S. Factors That Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring Frequency or Transition to Watchful Waiting for Localised Prostate Cancer: A Qualitative Study. *BMJ Open.* 2021;11:1–6.
73. Abedi AR, Ghiasy S, Fallah-Karkan M, Rahavian A, Allameh F. The Management of Patients Diagnosed with Incidental Prostate Cancer: Narrative Review. *Res Reports Urol.* 2020;12:105–9.
74. Cao X, Zhu J, Deng H. Prostate Cancer Radiotherapy: Current Status, Clinical Challenges, and Future Strategies. *Curr Res Med Sci.* 2025;4(2):55–7.
75. Slevin F, Zattoni F, Checcucci E, Cumberbatch MGK, Nacchia A, Cornford P, et al. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer. *Eur Urol Oncol.* 2024;7(4):677–96.
76. Moll M, Nechvile E, Kisisits C, Komina O, Pajer T, Kohl B, et al. Radiotherapy in Localized Prostate Cancer: A Multicenter Analysis Evaluating Tumor Control and Late Toxicity After Brachytherapy and External Beam Radiotherapy in 1293 Patients. *Strahlentherapie und Onkol.* 2024;200:698–705.
77. Kamran SC, D'Amico A V. Radiation Therapy for Prostate Cancer. *Hematol Oncol Clin North Am.* 2020;34(1):45–69.
78. Safriadi F, Umbas R, Danarto, Hakim L, Warli SM, Hamid AR, et al. *Panduan Penanganan Kanker Prostat. Revisi Ed.* Jakarta: Ikatan Ahli Urologi Indonesia; 2022. 9 p.
79. van Leenders GJLH, Verhoef EI, Hollemans E. Prostate Cancer Growth Patterns Beyond the Gleason Score: Entering a New Era of Comprehensive Tumour Grading. *Histopathology.* 2020;77:850–61.
80. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. *Eur Urol.* 2016;1–15.
81. Fatima G, Abeer, Babar K, Imran M, Iqbal J, Tariq T. Androgen Receptor (AR) Expression in Different Gleason Scores of Prostatic Adenocarcinoma by Immunohistochemistry. *J Fatima Jinnah Med Univ.* 2022;16:38–41.
82. Li Y, Huang M, Zhang Y, Chen J, Xu H, Wang G, et al. Automated Gleason Grading and Gleason Pattern Region Segmentation Based on Deep Learning for Pathological Images of Prostate Cancer. *IEEE Access.* 2020;8:117715.

83. Haffner MC, Salles DC, Gao G, Epstein JI. Gleason Pattern 4 with Cribriform Morphology on Biopsy is Associated with Adverse Clinicopathological Findings in A Prospective Radical Prostatectomy Cohort. *Hum Pathol*. 2020;98:75.
84. Inamura K. Prostatic Cancers: Understanding Their Molecular Pathology and the 2016 WHO Classification. *Oncotarget*. 2018;9(18):14723–37.
85. Zhou Y, Lin C, Hu Z, Yang C, Zhang R, Ding Y, et al. Differences in Survival of Prostate Cancer Gleason 8–10 Disease and the Establishment of a New Gleason Survival Grading System. *Cancer Med*. 2021;10:87–97.
86. Swanson GP, Trevathan S, Hammonds KAP, Speights VO, Hermans MR. Gleason Score Evolution and the Effect on Prostate Cancer Outcomes. *Am J Clin Pathol*. 2021;155:711–7.
87. Sastroasmoro S, Ismael S. *Dasar-Dasar Metodologi Penelitian Klinis*. 4th ed. BW S, Sastroasmoro S, editors. Jakarta: CV. Sagung Seto; 2011. 109–112 p.
88. Clark R, Vesprini D, Narod SA. The Effect of Age on Prostate Cancer Survival. *Cancers (Basel)*. 2022;14:1–2.
89. Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and Genomics of Prostate Cancer in Asian Men. *Nat Rev Urol*. 2021;18:282–301.
90. Varaprasad GL, Gupta VK, Prasad K, Kim E, Tej MB, Mohanty P, et al. Recent Advances and Future Perspectives in the Therapeutics of Prostate Cancer. *Exp Hematol Oncol*. 2023;12(80):2.
91. Mohajan D, Mohajan HK. Body Mass Index (BMI) is a Popular Anthropometric Tool to Measure Obesity Among Adults. *J Innov Med Res*. 2023;2(4):25–33.
92. Murugesan A, S.M. G. Prostate Carcinoma : Urologist's Perspective. *J Gastrointest Abdom Radiol ISGAR*. 2024;7(2):95–8.
93. Widodo S, Ladyani F, Asrianto LO, Rusdi, Khairunnisa, Lestari SMP, et al. *Buku Ajar Metode Penelitian*. 1st ed. Sudirman MS, editor. Pangkalpinang: CV Science Techno Direct; 2023.
94. Ulfaningtyas K, Norahmawati E, Anita KW, Angelina A, Seputra KP. Profil Klinikopatologi Adenokarsinoma Prostat di RSUD Dr. Saiful Anwar Malang Periode Tahun 2015 - 2019: Sebuah Penelitian Retrospektif. *Maj Kesehat*. 2021;8(2):87–99.
95. Scheipner L, Incesu RB, Morra S, Baudo A, Assad A, Jannello L, et al. Characteristics of Incidental Prostate Cancer in the United States. 2023;1–15.
96. National Cancer Institute. Cancer Stat Facts: Prostate Cancer [Internet]. National Institutes of Health. 2025 [cited 2025 Nov 11]. Available from: <https://seer.cancer.gov/statfacts/html/prost.html>

97. Nainggolan FKG, Christina S, Boedijono F, Angeline R. Gambaran Klinis dan Histopatologi Karsinoma Prostat di Salah Satu RS Swasta Jakarta Barat Tahun 2021-2023. 2025;4(1):29–35.
98. Ugwumba FO, Nnabugwu II. Prostate Cancer Characteristics : A Descriptive Analysis of Clinical Features at Presentation in the Last Decade in a Black African Community. 2022;153–7.
99. Barrett R, Birch B. Triptorelin Therapy for Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients : A Systematic Meta-Analysis. 2024;17–28.
100. Holtedahl K, Borgquist L, Donker GA, Buntinx F, Weller D, Campbell C, et al. Symptoms and Signs of Urogenital Cancer in Primary Care. BMC Prim Care. 2023;24:1–15.
101. Elsaqa M, El Tayeb MM. The Role of Transurethral BPH Surgeries in Management of Urinary Symptoms in Prostate Cancer Patients, Narrative Review. Curr Urol Rep. 2025;26(7):1–7.
102. Homalessy VC, Christina S, Sumbayak EM. Hubungan Indeks Massa Tubuh dengan Kejadian Kanker Prostat dan Gleason Score di Rumah Sakit Siloam Kupang. J MedScientiae. 2022;1(1):97–101.
103. Ngowi BN, Mremi A, Seif M, Bright F, Lyimo G, Uggh I, et al. High Body Mass Index Increases the Risk for Prostate Cancer and High Gleason Score in Northern Tanzania : Data from Prostate Cancer Screening. 2025;1–8.
104. Jochems SHJ, Stattin P, Häggström C, Järnholm B, Orho-melander M, Wood AM, et al. Height, Body Mass Index and Prostate Cancer Risk and Mortality by way of Detection and Cancer Risk Category. 2020;147:3328–38.
105. Wilson RL, Taaffe DR, Newton RU, Hart NH, Lyons-wall P, Galv DA. Obesity and Prostate Cancer : A Narrative Review. 2022;169:1–7.
106. Pratiwi NET, Riastiti Y, Irawiraman H, Danial. Hubungan Usia dan Kadar Prostate Specific Antigen (PSA) dengan Derajat Histopatologi Adenokarsinoma Prostat di RSUD Abdoel Wahab Sjahranie Samarinda. J Kesehat Andalas. 2023;12(2):64–9.
107. Prasetya GR, Saraswati M, Hamid ARA, Matondang SB. Profil Klinikopatologik Kasus Adenokarsinoma Prostat di RSCM Tahun 2010-2019 dengan Tinjauan Khusus Biopsi Robotik. 2022;31(3):462–70.
108. Ngowi BN, Mremi A, Seif MJ, Kyara YS, Mteta VK, Bright F, et al. Prostate Cancer : Burden and Correlation with Prostate Specific Antigen Among Screened African Men in Tanzania. 2024;16:315–25.
109. Zhang Z, Tian A, Che J, Miao Y, Liu Y, Liu Y, et al. Application and Optimization of Prostate-Specific Antigen Screening Strategy in the Diagnosis of Prostate Cancer : A Systematic Review. Front Oncol. 2024;13:1–11.

110. Neeli S, Sharma M, Musale A. Prostate-Specific Antigen : An Overview and its Current Status in the Diagnosis. *Indian J Heal Sci Biomed Res.* 2021;14(1):22–30.
111. Abdurrahman F, Suryanti S, Sihombing AT. The Relationship between Body Mass Index (BMI) and Gleason Score of Indonesian Prostate Cancer Men in Hasan Sadikin General Hospital. 2018;2(2):780–7.
112. Navisa CC, Sandhika W, Arwati H. Hubungan antara Kadar Prostate Specific Antigen Serum dan Skor Gleason pada Adenokarsinoma Prostat. 2019;30(3):181–4.
113. Raphael JE, Abhulimen V. Age and Gleason’s Score in Prostate Cancer among Southern Nigerians : Is there Any Correlation? 2022;12(2):8–15.
114. Klotz L. Active Surveillance in Intermediate-Risk Prostate Cancer. *BJU Int.* 2020;125:346–54.
115. Muralidhar V, Ziehr DR, Mahal BA, Chen Y wei, Nezoslosky MD, Viswanathan VB, et al. Association Between Older Age and Increasing Gleason Score. *Clin Genitourin Cancer.* 2015;6:1–6.
116. Kisiel F, Ferguson D, Hart C, Brown M, Oliveira P, Sachdeva A, et al. Prognostic Significance of PTEN Loss in Prostate Cancer : A Meta-Analysis of Gleason Grade and Clinical Outcomes. 2025;17(17):1–19.
117. Amirah VA. Hubungan Usia dan IMT dengan Gleason Score pada Penderita Kanker Prostat di RSUP Dr. Mohammad Hoesin Palembang. *Sriwijaya University*; 2022.
118. Cruz JAS da, Passerotti CC, Reis ST dos, Guariero MES, Campos OD de, Leite KRM, et al. Is Age an Independent Factor for Prostate Cancer? A Paired Analysis. *Curr Urol.* 2016;9:183–7.
119. Abdullah A, Ali N, Malik Z. To Evaluate the Corelation between Age and Gleason Score in Patients with Prostate Cancer- A Tertiary Care Hospital Based Study. *Liaquat Natl J Cancer Care.* 2021;3(1):7–10.
120. Huynh-Le MP, Myklebust TÅ, Feng CH, Karunamuni R, Johannesen TB, Dale AM, et al. Age Dependence of Modern Clinical Risk Groups for Localized Prostate Cancer – A Population-Based Study. *Cancer.* 2021;126(8):1691–9.
121. Mugarura R, Lule J, Akello J, Katushabe M, Mugisha J, Maniple EB. Prevalence of Prostate Cancer and its Grade Group Stage at Diagnosis in Patients Treated with Prostatectomy in Rural South Western Uganda. *BMC Urol.* 2024;24(286):1–5.
122. Taborrelli M, Serraino D, Toffolutti F, Bidoli E, Vidi S De, Fratino L, et al. Trends in Prostate Cancer Incidence and Survival by Gleason Score from 2000 to 2020 : A Population-Based Study in Northeastern Italy. *Curr Oncol.* 2025;32:1–11.

123. Udoh EA, Charles NC, Essiet IU. Is There any Relationship between Age of Patients and Prostate Cancer Aggressiveness? *Int J Contemp Med Res.* 2020;7(5):5–9.
124. Mohammed U, Rasheed M., Adegboye A., Abdullahi K, Sahabi S., Mohammed T, et al. Correlation of Serum PSA with Gleason Score and Gleason Group Grade in Patients with Prostate Adenocarcinoma at Sokoto North-Western Nigeria. *Int J Recent Innov Med Clin Res.* 2020;2(1):1–8.
125. Al-Zubaidi M, Hawks C, Fernando S, Moe A, Swarbrick N, McCombie SP, et al. Relationship between Lower Urinary Tract Symptoms (LUTS) and Prostate Cancer : A Persistent Myth. *J Clin Urol.* 2023;18(2):1–8.
126. Kyegombe W, Ronald O, Nimusima A, Nsubuga Y, Nakitto B, Nannungi C, et al. Prostate Cancer Among Patients Presenting with Obstructive Lower Urinary Tract Symptoms at a Tertiary Hospital in South Western Uganda. *Res Reports Urol.* 2025;17:367–81.
127. Bhindi A, Bhindi B, Kulkarni GS, Hamilton RJ, Toi A, Kwast TH van der, et al. Modern-Day Prostate Cancer is Not Meaningfully Associated with Lower Urinary Tract Symptoms : Analysis of a Propensity Score- Matched Cohort. *Can Urol Assoc.* 2017;11(1–2):41–6.
128. Mazlouni SA, Moudi E, Shafi H, Gholinia H. Association of BMI and Age with Gleason Score and PSA in Patients with Prostate Cancer. *J Babol Univ Med Sci.* 2023;25(1):455–62.
129. Nwadi UV, Maduaburochukwu A, Nwofor E, Oranusi CK, Orakwe JC, Obiesie EA, et al. Correlation between Body Mass Index and Gleason Score in Men with Prostate Cancer in Southeastern Nigeria. *Niger J Surg.* 2021;27:22–7.
130. Chamie K, Oberfoell S, Kwan L, Labo J, Wei J, Litwin M. BMI and Prostate Cancer Severity: Do Obese Men Harbor More Aggressive Disease on Prostate Biopsy? *Urology.* 2014;81(5):949–55.
131. Kruk J, Bernstein J, Aboul-Enein BH. Obesity, Physical Activity and Prostate Cancer: An Overview. *Cent Eur J Sport Sci Med.* 2022;38(2):71–91.
132. Vitale E, Rizzo A, Halemani K, Shetty AP, Cauli O, Massari F, et al. Normal Weight, Overweight and Obesity Conditions Associated to Prostate Neoplasm Stages — A Systematic Review and Meta-Analysis. *Biomedicines.* 2025;13(5):1–20.
133. Choi JB, Myong J pyo, Lee Y, Kim I, Kim JH, Hong S hoo, et al. Does Increased Body Mass Index Lead to Elevated Prostate Cancer Risk? It Depends on Waist Circumference. *BMC Cancer.* 2020;20(589):1–8.
134. Herawan MIAK, Adriansjah R. Prostate Specific Antigen Level and Gleason Score in Indonesian Prostate Cancer Patients. *Maj Kedokt Bandung.* 2024;56(3):209–13.

135. Maharjan PB, Karki S, Chalise PR, Ghimire P. Correlation of Serum Prostate-Specific Antigen with Gleason score and Gleason Grade Group in Patients with Prostate Adenocarcinoma at A Tertiary Care Hospital. *J Pathol Nepal*. 2025;15(2025).
136. Veríssimo I de A, Oliveira HR, Aguiar GLA, Moreno FB da S, Abreu MS de, Veríssimo L de A, et al. Retrospective Study of the Relationship between Gleason Score and Prostate-Specific Antigen (PSA) Initial in the Presence of Metastases. *Res Soc Dev*. 2024;13(11):1–11.
137. Doroudinia A, Darvishian N, Karam MB, Emami H. Evaluation of the Relationship Between Prostate-Specific Antigen Levels, Gleason Scores, and 68Ga-PSMA PET/CT Scan Findings in Prostate Cancer Patients. *Iran J Radiol*. 2022;19(1):1–5.
138. Mahal BA, Aizer AA, Efsthathiou JA, Nguyen PL. Association of Very Low Prostate-Specific Antigen Levels with Increased Cancer-Specific Death in Men with High-Grade Prostate Cancer. 2016. p. 78–83.
139. Rani E, Nibhoria S, Nagpal N. Outlook of Gleason Score in Prostate Carcinoma and Correlation with PSA Levels : A study in a Tertiary Care Hospital. *J Cancer Res Ther*. 2023;19(5):1305–10.
140. Sharma R, Bansal M, Sharma HB, Kumar N, Vinish, Gupta M, et al. Correlation of Serum Prostate-Specific Antigen with Gleason's Score Grade Group in Prostate Cancers and their Histopathological Findings: A 4-Year Retrospective Study at a Tertiary Care Center. *J Sci Soc*. 2023;50(3):351–5.
141. Godbole CR, Bhide SP. Study of Histopathological Correlation of Prostate Lesions with Serum Prostate Specific Antigen Levels in a Tertiary Care Hospital. *MedPulse Int J Pathol*. 2020;13(3):125–9.
142. Pushpa, Goyal N, Ritul, Bhamu S. Histopathological Spectrum of Prostatic Lesions and Their Correlation with Serum Prostate Specific Antigen Levels. *Asian J Pharm Clin Res*. 2024;17(2):36–9.
143. Gurumurthy D, Maggad R, Patel S. Prostate Carcinoma: Correlation of Histopathology with Serum Prostate Specific Antigen. *Sci J Clin Med*. 2015;4(4–1):1–5.
144. Udoh EA, David DE, Eyo AE. Relationship between Serum Prostate Specific Antigen (PSA) and Gleason Score in Patients Diagnosed with Prostate Cancer. A Hospital Based Study. *East African Sch J Med Surg*. 2020;2(2):47–52.